Photo of Tatiana Prowell taken from www.bard.edu
Sep 25, 2023, 22:17
Tatiana Prowell: The first standardized definitions for efficacy endpoints in neoadjuvant breast cancer clinical trials (NeoSTEEP) are published in Journal of Clinical Oncology.
Tatiana Prowell, Breast Cancer Scientific Lead at Office of Hematology & Oncology Products, US Food & Drug Administration, made the following post on Twitter:
“The first standardized definitions for efficacy endpoints in neoadjuvant breast cancer clinical trials (NeoSTEEP) are published in Journal of Clinical Oncology. Honored to have been a part of this working group. No paywall. Regulatory Drug development.”
For details click here.
Source: Tatiana Prowell/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14